Hanny Al-Samkari, MD, Massachusetts General Hospital, Boston, MA, discusses the mechanism of action (MOA) of mitapivat, a novel activator of pyruvate kinase that can stimulate ATP production, and highlights ongoing studies that are assessing mitapivat's efficacy in pyruvate kinase deficiency (PKD), thalassemia, and sickle cell disease (SCD). This interview took place at the 64th ASH Annual Meeting and Exposition congress held in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
